WO2005058233B1 - Methods for treatment of acute pancreatitis - Google Patents
Methods for treatment of acute pancreatitisInfo
- Publication number
- WO2005058233B1 WO2005058233B1 PCT/US2004/041368 US2004041368W WO2005058233B1 WO 2005058233 B1 WO2005058233 B1 WO 2005058233B1 US 2004041368 W US2004041368 W US 2004041368W WO 2005058233 B1 WO2005058233 B1 WO 2005058233B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- secretin
- pharmaceutical composition
- patient
- acute pancreatitis
- human
- Prior art date
Links
- 206010033647 Pancreatitis acute Diseases 0.000 title claims abstract 5
- 201000003229 acute pancreatitis Diseases 0.000 title claims abstract 5
- OWMZNFCDEHGFEP-NFBCVYDUSA-N L-Histidyl-L-seryl-L-a-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-a-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-a-glutamylglycyl -L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leu Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims abstract 12
- 229950002350 secretin human Drugs 0.000 claims abstract 12
- 102100001186 SCT Human genes 0.000 claims abstract 11
- 229960002101 Secretin Drugs 0.000 claims abstract 11
- 108010086019 Secretin Proteins 0.000 claims abstract 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 235000002639 sodium chloride Nutrition 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- JWQZOTGHUDZFMU-WIDFLDSMSA-N 17034-35-4 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 JWQZOTGHUDZFMU-WIDFLDSMSA-N 0.000 claims 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 claims 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims 1
- 229940063655 Aluminum stearate Drugs 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229960002449 Glycine Drugs 0.000 claims 1
- 229940097698 Human Secretin Drugs 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006822 Human Serum Albumin Proteins 0.000 claims 1
- 229940067606 Lecithin Drugs 0.000 claims 1
- 229920001451 Polypropylene glycol Polymers 0.000 claims 1
- 229940069338 Potassium Sorbate Drugs 0.000 claims 1
- CHHHXKFHOYLYRE-STWYSWDKSA-M Potassium sorbate Chemical compound [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 claims 1
- 229950008679 Protamine sulfate Drugs 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 229940075582 Sorbic Acid Drugs 0.000 claims 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 claims 1
- 210000002268 Wool Anatomy 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims 1
- 235000019797 dipotassium phosphate Nutrition 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 239000000391 magnesium silicate Substances 0.000 claims 1
- 229940099273 magnesium trisilicate Drugs 0.000 claims 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims 1
- 235000019793 magnesium trisilicate Nutrition 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 235000010241 potassium sorbate Nutrition 0.000 claims 1
- 239000004302 potassium sorbate Substances 0.000 claims 1
- -1 protamine sulfate Chemical class 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 150000003751 zinc Chemical class 0.000 claims 1
Abstract
The invention relates generally to methods for treating acute pancreatitis in patients. The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier.
Claims
AMENDED CLAIMS
[received by the International Bureau on 23 December 2005 (23.12.05); original claim 1 amended; original claim 10 cancelled remaining claims unchanged (4 pages)]
+ STATEMENT
WHAT IS CLAIMED IS:
1. A method for treating acute pancreatitis in a human patient, comprising the step of administering to a human patient suffering from acute pancreatitis a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable qarrier, said pharmaceutical composition capable of treating said acute pancreatitis in said human
patient.
t. The method of claim 1 , wherein said secretin is a naturally occurring form of secretin.
3. The method of claim 1 , wherein said secretin is a synthetic form of secretin.
4, The method of claim 3, wherein said synthetic form of secretin is synthetic porcine secretin.
$. The method of claim 1 , wherein said secretin is a genetically recombined form of porcine, bovine, or human secretin.
6. The method of claim 1 , wherein the amount of secretin administered to said patient in said pharmaceutical composition ranges from 2 to 480 micrograms per day.
7. The method of claim 6, wherein the amount of secretin administered to said patient in said pharmaceutical composition ranges from 24 to 160 micrograms per day.
19
8. The method of claim 7, wherein the amount of secretin administered to said patient in said pharmaceutical composition ranges from 48 to 128 micrograms per day.
$ . The method of claim 1, wherein said pharmaceutically acceptable carrier is selected from fie group consisting of ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride (saline), zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat, and combinations thereof.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52943303P | 2003-12-12 | 2003-12-12 | |
| US60/529,433 | 2003-12-12 | ||
| US11/007,490 US7381698B2 (en) | 2003-12-12 | 2004-12-08 | Methods for treatment of acute pancreatitis |
| US11/007,490 | 2004-12-08 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2005058233A2 WO2005058233A2 (en) | 2005-06-30 |
| WO2005058233A3 WO2005058233A3 (en) | 2005-12-29 |
| WO2005058233B1 true WO2005058233B1 (en) | 2006-03-02 |
Family
ID=34656445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/041368 WO2005058233A2 (en) | 2003-12-12 | 2004-12-10 | Methods for treatment of acute pancreatitis |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US7381698B2 (en) |
| WO (1) | WO2005058233A2 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632429B1 (en) * | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US8100844B2 (en) * | 2002-04-25 | 2012-01-24 | Ultraflex Systems, Inc. | Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
| US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| WO2010002972A1 (en) * | 2008-07-01 | 2010-01-07 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) * | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| ES2727746T3 (en) | 2009-01-06 | 2019-10-18 | Galenagen Llc | Oral compositions for the treatment or prevention of E. coli infections |
| NZ593831A (en) | 2009-01-06 | 2013-09-27 | Curelon Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
| WO2012145651A2 (en) | 2011-04-21 | 2012-10-26 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
| US9962430B2 (en) | 2012-02-15 | 2018-05-08 | Chirhoclin, Inc. | Methods for treating pain associated with chronic pancreatitis |
| US11406718B2 (en) | 2012-05-29 | 2022-08-09 | Chirhoclin, Inc. | Methods of detecting pancreobiliary ductal leaks |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| RU2738669C1 (en) * | 2020-07-27 | 2020-12-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Ижевская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Method of treating acute pancreatitis |
| US11744878B2 (en) | 2020-08-19 | 2023-09-05 | Chirhoclin, Inc. | Methods for treatment of COVID-19 syndrome |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| CN113424795B (en) * | 2021-05-24 | 2022-09-09 | 四川大学华西医院 | Construction method and application of acute pancreatitis animal model |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443434A (en) * | 1982-08-18 | 1984-04-17 | American Home Products Corporation | Antiulcer agent |
| JPS59186916A (en) * | 1983-04-06 | 1984-10-23 | Aiji Noda | Remedy for pancreatolithiasis |
| US5094837A (en) * | 1990-01-22 | 1992-03-10 | Wayne State University | Method for use of magnetic resonance imaging to image pancreas using secretin |
| AU748147B2 (en) * | 1997-05-19 | 2002-05-30 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| US6776990B2 (en) * | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6534063B1 (en) * | 1999-12-17 | 2003-03-18 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
| US6261572B1 (en) * | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| WO2001079837A1 (en) * | 2000-04-12 | 2001-10-25 | Repligen Corporation | Methylxanthines in the diagnosis and treatment of autistic disorder |
| WO2003045322A2 (en) * | 2001-11-28 | 2003-06-05 | Schering Corporation | Method for treating and preventing pancreatitis |
-
2004
- 2004-12-08 US US11/007,490 patent/US7381698B2/en active Active
- 2004-12-10 WO PCT/US2004/041368 patent/WO2005058233A2/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005058233B1 (en) | Methods for treatment of acute pancreatitis | |
| Matthews et al. | Peptide absorption | |
| Whitesst et al. | Hydrophobic surfactant-associated protein in whole lung surfactant and its importance for biophysical activity in lung surfactant extracts used for replacement therapy | |
| Wiedow et al. | Elafin is a potent inhibitor of proteinase 3 | |
| Hunter et al. | Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins | |
| Broekhuyse | Tear lactoferrin: a bacteriostatic and complexing protein | |
| EP0566135A1 (en) | Transmucosal composition comprising a peptide and a cytidine derivative | |
| JPH06316530A (en) | Local insulin-containing preparation | |
| JP3176604B2 (en) | Factor Xa inhibitor and pharmaceutical composition containing the same | |
| JPH09512552A (en) | Methods and compositions for treating renal diseases and disorders | |
| AU2008100924A4 (en) | Dermatologic use of milk proteins | |
| IL135186A0 (en) | LIQUID INTERFERON-β FORMULATIONS | |
| MY125414A (en) | Aminopropylphosphinic acids | |
| CA2188172A1 (en) | Human bone stimulating factor | |
| WO2002043746A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
| WO1993005809A1 (en) | Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating or preventing myointimal proliferation | |
| CA2196906A1 (en) | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions | |
| MX9703642A (en) | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein. | |
| NL8003802A (en) | MIXTURE BASED ON COLOSTRUM FOR EXTERNAL USE. | |
| RU99103692A (en) | AMINO ACID COMPOSITIONS AND THEIR APPLICATION IN IMMUNO DEPRESSION | |
| WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
| CA2134380C (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
| AU671850B2 (en) | Peptide lung surfactants and therapeutic combinations | |
| Dupont et al. | Effect of propylthiouracil and thyroxine on the inactivation of somatostatin by rat hypothalamus | |
| CA2492378A1 (en) | Modified amino acid for the inhibition of platelet aggregation |